Access for All was launched in 2019 and has already driven major change. We are fortunate to have some of the most powerful young voices in the country advocating for our mission. These dedicated individuals have rallied communities across the country, and now several provinces and territories are in the process of revisiting their coverage […]
Summer is here and as Canadians are getting vaccinated against COVID-19, we have decided to take a break from our live Let’s Talk T1D events on Microsoft Teams, and package them in a way that is more convenient for the summer months. More Canadians are getting vaccinated against COVID-19 and restrictions across the country are easing. The […]
Type 1 diabetes is an autoimmune disease resulting in a lifelong dependency on insulin treatment and a risk of serious long-term complications. The cause of the disease is unclear, although both genes and factors in the environment seem to be important. As new cases of this burdensome and costly disease are on the rise in […]
We’re heading into the summer, and after a long Canadian winter, many of us are more than ready to head outdoors. But the summer season also means some different planning when managing type 1 diabetes (T1D). Please find below some tips and suggestions to help you get the most out of the sunny days. COVID-19 […]
Joseph Segal is a 96-year-old World War II vet and renowned business tycoon. As the founder of Fields stores and President of Kingswood Capital Corporation, Joseph Segal has built an impressive empire, but perhaps his most tremendous success comes in the form of his and his family’s philanthropy. Recently, JDRF was the recipient of his […]
Adolescence can be a challenging time to manage type 1 diabetes (T1D). Life (and hormones!) change in all sorts of ways, and many teenagers experience higher than recommended blood glucose levels as a result, which can mean an increased risk of complications later in life. The study of novel therapies that can improve glycemic control […]
Canada holds a special place in the story of insulin because scientists Banting and Best made the discovery at the University of Toronto, in 1921. Before the discovery, the lives of people with diabetes were often cut short and the disease often resulted in death. Insulin’s discovery revolutionized the treatment of diabetes, increased life expectancy and changed […]
This June, Canadians from coast to coast will be coming together to unite, raise funds and help accelerate the pace of type 1 diabetes (T1D) research as part of the 2021 Sun Life Walk to Cure Diabetes for JDRF. This year is a big one…we’re commemorating 100 years since the discovery of the life-changing drug […]
JDRF Canada is thrilled that federal budget 2021 includes new funding for type 1 diabetes research, as well as support for a national diabetes framework and improvements to the Disability Tax Credit (DTC). Of the $35 million investment to honour the centenary of the discovery of insulin, JDRF is awaiting further details to better understand how this investment will […]
May 4th, 2021 “Insulin is not a cure for diabetes; it is a treatment.” – Dr. Frederick Banting 2021 marks the 100th anniversary of the discovery of insulin by researchers Dr. Frederick Banting and Charles Best at the University of Toronto. Before insulin treatment, a diagnosis of type 1 diabetes (T1D) meant inevitable death for […]
Update: May 3, 2021: Ontario: As of May 10, 2021 anyone over 16 with type 1 diabetes can book a vaccine throughout the province. Alberta: Children aged 12 -15 with type 1 diabetes are no longer required to present a doctor’s note when booking a vaccine. Anyone over 16 with type 1 diabetes is also eligible for […]
May 4th, 2021 On April 15, 2021 the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation for vTv Therapeutics’ TTP399 as an adjunct therapy to insulin for type 1 diabetes (T1D). This designation is intended to expedite the development and review of drugs for serious and life-threatening conditions. TTP399 is a liver-selective glucokinase (or GK) […]
